Synaptic Resilience Enhancement for Pre-Symptomatic Neurodegeneration Prevention
Overview
This therapeutic concept proposes synaptic resilience enhancement for individuals identified as pre-symptomatic for neurodegenerative diseases. By targeting synaptic proteins (neurogranin), receptors, and downstream signaling pathways before significant synapse loss occurs, this approach aims to preserve cognitive function and prevent progression to clinical disease.[@masliah2001]
Rationale
Synapse loss correlates with cognitive decline: Post-mortem studies show synapse loss is the strongest correlate of cognitive impairment in both AD and PD[@spiresjones2014]
Neurogranin is an early biomarker: Elevated CSF neurogranin predicts future cognitive decline in pre-symptomatic individuals[@kvartsberg2015]
Synaptic plasticity is modifiable: NMDA receptor modulation, BDNF signaling, and synaptic protein synthesis can be enhanced pharmacologically[@malenka2004]
Early intervention critical: Synapse loss becomes irreversible once advanced; pre-symptomatic intervention offers the best chance of preservation[@selkoe2002]
Mechanistic Logic
```mermaid flowchart TD subgraph Risk_Identification A["Cognitive Testing<br/>RAVLT, ECAS"] --> B["CSF Neurogranin<br/>Elevated = synaptic vulnerability"] B --> C["High Synaptic Risk"] end
...
Synaptic Resilience Enhancement for Pre-Symptomatic Neurodegeneration Prevention
Overview
This therapeutic concept proposes synaptic resilience enhancement for individuals identified as pre-symptomatic for neurodegenerative diseases. By targeting synaptic proteins (neurogranin), receptors, and downstream signaling pathways before significant synapse loss occurs, this approach aims to preserve cognitive function and prevent progression to clinical disease.[@masliah2001]
Rationale
Synapse loss correlates with cognitive decline: Post-mortem studies show synapse loss is the strongest correlate of cognitive impairment in both AD and PD[@spiresjones2014]
Neurogranin is an early biomarker: Elevated CSF neurogranin predicts future cognitive decline in pre-symptomatic individuals[@kvartsberg2015]
Synaptic plasticity is modifiable: NMDA receptor modulation, BDNF signaling, and synaptic protein synthesis can be enhanced pharmacologically[@malenka2004]
Early intervention critical: Synapse loss becomes irreversible once advanced; pre-symptomatic intervention offers the best chance of preservation[@selkoe2002]
Mechanistic Logic
Mermaid diagram (expand to render)
Target Population
| Risk Category | Profile | Age Range | Biomarker Criteria | |---------------|---------|-----------|-------------------| | High Risk | Family history + elevated neurogranin | 50-70 | CSF neurogranin > elevated | | Moderate Risk | Genetic risk (APOE4/LRRK2) | 45-65 | Normal cognition, subtle deficits | | Prodromal | MCI with biomarker evidence | 55-75 | MCI, positive AD/PD biomarkers |
Key Components
Pharmacologic Interventions
Low-dose memantine: Sub-antagonistic NMDA doses that enhance synaptic plasticity without causing adverse effects[@lipton2007]
Lobeline: Amphetamine derivative that enhances dopamine release and protects synapses[@teng2010]
NSI-189: Novel compound that promotes hippocampal neurogenesis and synaptic protein expression[@fischer2017]
Sage-217 (SAGE-217): GABA-A modulator in development for cognitive enhancement[@gunther2018]
Amplification Approaches
CK2 inhibition: Enhance synaptic protein synthesis and stability[@giese2012]
| Phase | Design | Population | Primary Endpoint | |-------|--------|------------|-----------------| | II | Randomized, placebo-controlled | Elevated neurogranin, age 50-75 | Change in synaptic PET at 12 months | | III | Factorial design | Pre-symptomatic at-risk | Time to cognitive impairment |